{"id":861738,"date":"2025-06-18T10:41:49","date_gmt":"2025-06-18T14:41:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/"},"modified":"2025-06-18T10:41:49","modified_gmt":"2025-06-18T14:41:49","slug":"lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/","title":{"rendered":"Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)"},"content":{"rendered":"<h2>\nOral presentation on study demonstrating the ability of sotagliflozin to reduce the risk of hypoglycemic events regardless of kidney function in people with type 1 diabetes<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">THE WOODLANDS, Texas, June  18, 2025  (GLOBE NEWSWIRE) &#8212; \u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7yxQ4wzB4_YG206938PMqBcDTpHle7Bd3vjzkbweOvUFrv6vYjdmp-tVYekJfWOlrdyxxgVHfZUqkEl9WIEOGl2sMeYfQJOaWJ98MHnF0l0bEIesku9mxQ1gRn-WDKCi\" rel=\"nofollow\" target=\"_blank\"><u>Lexicon Pharmaceuticals, Inc.<\/u><\/a>\u00a0(Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia in people with type 1 diabetes will be delivered as an oral presentation on Sunday, June 22, during the 85th Scientific Sessions of the American Diabetes Association (ADA). At the meeting, the company will also present topline data from its PROGRESS Phase 2b study evaluating pilavapadin (LX9211) in adults with diabetic peripheral neuropathic pain. The congress is being held June 20\u201323, 2025 at the McCormick Place Convention Center in Chicago, Illinois.<\/p>\n<p>The ADA recently emphasized that hypoglycemia remains an important patient management issue in type 1 diabetes. Its <em>Standards of Care in Diabetes &#8212; 2025 <\/em>clinical update states, \u201cHealth care professionals should be vigilant in preventing hypoglycemia.\u201d<\/p>\n<p>In a session entitled \u201cInterventions to Prevent Hypoglycemia: Bench to Bedside,\u201d Lexicon US Medical Affairs team member M. Belinda Hardin, PharmD, BCPS, will present sotagliflozin clinical efficacy data segmented by three common kidney-function subgroups: Estimated Glomerular Filtration Rate (eGFR) of &lt; 60 ml\/min\/1.73m<sup>2<\/sup>, \u2265 60 to &lt; 90 ml\/min\/1.73m<sup>2<\/sup>, and \u2265 90 ml\/min\/1.73m<sup>2<\/sup>.<\/p>\n<p>\u201cWe appreciate the opportunity to share our study results in an oral presentation at this important gathering of the diabetes community,\u201d said Craig Granowitz, M.D., Ph.D., Lexicon\u2019s senior vice president and chief medical officer. \u201cWe anticipate lively discussions following Dr. Hardin\u2019s presentation and throughout the \u2018Interventions to Prevent Hypoglycemia\u2019 session.\u201d<\/p>\n<p>Presentation details:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>\u201cSotagliflozin Added to Insulin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes Regardless of Kidney Function\u201d <\/strong>&#8212; Sunday, June 22, 4:00-4:15 p.m. CT, Presentation 244-OR, W181 A-C, presented by M. Belinda Hardin, PharmD, BCPS, US Medical Affairs, Lexicon Pharmaceuticals, Inc. on behalf of the inTandem study investigators<\/p>\n<\/li>\n<\/ul>\n<p>During the 85th Scientific Sessions, Lexicon also will present topline data from its PROGRESS Phase 2b study evaluating pilavapadin (LX9211) in adults with diabetic peripheral neuropathic pain.<\/p>\n<p>Presentation details:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">\n          <strong>\u201cPilavapadin, an Oral, Non-opioid, AAK1 Inhibitor for Diabetic Peripheral Neuropathic Pain (DPNP)&#8211;Results from a Phase 2b, Dose-Ranging, Randomized, Multicenter Study\u201d<\/strong> &#8212; Sunday, June 22, 12:30-1:30 p.m. CT, Board No. 1876, Poster Hall F1 <\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong>About Sotagliflozin<\/strong><br \/>\n        <br \/>Discovered using Lexicon\u2019s unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients.<\/p>\n<p>\n        <strong>About the PROGRESS Study<\/strong>\u00a0<br \/>The PROGRESS study commenced in December 2023 and enrolled 496 adult patients with a diagnosis of diabetes (type 1 or type 2) and moderate to severe DPNP. The study was placebo-controlled with a primary endpoint of change from baseline to Week 8 in ADPS and evaluated three treatment groups receiving once daily pilavapadin doses of 10 mg, 20 mg or 20 mg for seven days followed by 10 mg thereafter. Secondary endpoints included change from baseline to Week 8 in burning pain and pain interference on sleep. Study design permitted patients to remain on one stable-dose DPNP therapy (e.g. gabapentin, pregabalin or duloxetine) without withdrawing from therapies that, although inadequate, may be providing some benefit\u00a0\u2014 aligning with how new DPNP drugs are likely to be used in practice.\u00a0<\/p>\n<p>\n        <strong>About DPNP<\/strong>\u00a0<br \/>DPNP is a debilitating chronic complication of diabetes which can result in burning pain, numbness, and other symptoms in the hands, feet, legs and arms. There are approximately 9 million patients in the U.S. who are suffering with DPNP.\u00a0<\/p>\n<p>\n        <strong>About Lexicon Pharmaceuticals\u202f\u00a0<\/strong>\u00a0<br \/>Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients\u2019 lives. Through the Genome5000\u2122 program, Lexicon\u2019s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications.\u202f For additional information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q1p2NGGrNd-LRWvHPiFjntJTdXpQN6foHYYVa9odYKgK4J7uGRsMifsxzkYckLyyeP4mHVL4NZU9e1JudV0_kpEFWUPiH3rSmYzEthPhopY=\" rel=\"nofollow\" target=\"_blank\"><u>www.lexpharma.com.<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor Statement<\/strong>\u202f\u00a0<br \/><em>This press release contains \u201cforward-looking statements,\u201d including statements relating to Lexicon\u2019s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon\u2019s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management\u2019s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon\u2019s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon\u2019s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under \u201cRisk Factors\u201d in Lexicon\u2019s annual report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.<\/em>\u202f\u00a0<\/p>\n<p>\n        <strong>For Investor and Media Inquiries<\/strong>:\u202f\u00a0<\/p>\n<p align=\"justify\">Lisa DeFrancesco\u202f\u202f\u00a0<br \/>Lexicon Pharmaceuticals, Inc.\u202f\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zujSbf93Ox-APZ6QJzUZll_qXJEaX5-BwnJko-OAC0alpBBnB4SmcdRihjtWuxPE32t3gHVlNewTJKRsBJRXFILqGz1wxQY8PmoXuRxag8dpopVIGyPZbiM-3dl-FcJz\" rel=\"nofollow\" target=\"_blank\"><u>lexinvest@lexpharma.com<\/u><\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MDYwMSM2OTk2OTE3IzIwMDM5Njc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjdjNzgyYjYtNzMxNy00NjQxLWJlZTktMDI4NDg5Y2VhMDQzLTEwMTU1NDAtMjAyNS0wNi0xOC1lbg==\/tiny\/Lexicon-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Oral presentation on study demonstrating the ability of sotagliflozin to reduce the risk of hypoglycemic events regardless of kidney function in people with type 1 diabetes THE WOODLANDS, Texas, June 18, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Lexicon Pharmaceuticals, Inc.\u00a0(Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia in people with type 1 diabetes will be delivered as an oral presentation on Sunday, June 22, during the 85th Scientific Sessions of the American Diabetes Association (ADA). At the meeting, the company will also present topline data from its PROGRESS Phase 2b study evaluating pilavapadin (LX9211) in adults with diabetic peripheral neuropathic pain. The congress is being held June 20\u201323, 2025 at the McCormick Place Convention &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-861738","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Oral presentation on study demonstrating the ability of sotagliflozin to reduce the risk of hypoglycemic events regardless of kidney function in people with type 1 diabetes THE WOODLANDS, Texas, June 18, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Lexicon Pharmaceuticals, Inc.\u00a0(Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia in people with type 1 diabetes will be delivered as an oral presentation on Sunday, June 22, during the 85th Scientific Sessions of the American Diabetes Association (ADA). At the meeting, the company will also present topline data from its PROGRESS Phase 2b study evaluating pilavapadin (LX9211) in adults with diabetic peripheral neuropathic pain. The congress is being held June 20\u201323, 2025 at the McCormick Place Convention &hellip; Continue reading &quot;Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-18T14:41:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MDYwMSM2OTk2OTE3IzIwMDM5Njc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)\",\"datePublished\":\"2025-06-18T14:41:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\\\/\"},\"wordCount\":1024,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MDYwMSM2OTk2OTE3IzIwMDM5Njc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\\\/\",\"name\":\"Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MDYwMSM2OTk2OTE3IzIwMDM5Njc=\",\"datePublished\":\"2025-06-18T14:41:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MDYwMSM2OTk2OTE3IzIwMDM5Njc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MDYwMSM2OTk2OTE3IzIwMDM5Njc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/","og_locale":"en_US","og_type":"article","og_title":"Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - Market Newsdesk","og_description":"Oral presentation on study demonstrating the ability of sotagliflozin to reduce the risk of hypoglycemic events regardless of kidney function in people with type 1 diabetes THE WOODLANDS, Texas, June 18, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Lexicon Pharmaceuticals, Inc.\u00a0(Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia in people with type 1 diabetes will be delivered as an oral presentation on Sunday, June 22, during the 85th Scientific Sessions of the American Diabetes Association (ADA). At the meeting, the company will also present topline data from its PROGRESS Phase 2b study evaluating pilavapadin (LX9211) in adults with diabetic peripheral neuropathic pain. The congress is being held June 20\u201323, 2025 at the McCormick Place Convention &hellip; Continue reading \"Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-18T14:41:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MDYwMSM2OTk2OTE3IzIwMDM5Njc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)","datePublished":"2025-06-18T14:41:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/"},"wordCount":1024,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MDYwMSM2OTk2OTE3IzIwMDM5Njc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/","name":"Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MDYwMSM2OTk2OTE3IzIwMDM5Njc=","datePublished":"2025-06-18T14:41:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MDYwMSM2OTk2OTE3IzIwMDM5Njc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MDYwMSM2OTk2OTE3IzIwMDM5Njc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-to-present-data-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/861738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=861738"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/861738\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=861738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=861738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=861738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}